Objectives: The widespread administration of carbapenems to patients with ESBL-producing Enterobacteriaceae bacteraemia (ESBL-B) has accelerated the emergence of carbapenem-resistant Enterobacteriaceae. This study aimed to systematically review recently published data to evaluate the clinical effectiveness of carbapenems, compared with other antibiotics, in the treatment of ESBL-B.
Introduction
Since the publication in the 1980s of reports that described the ability of b-lactamases to hydrolyse extended-spectrum cephalosporins, [1] [2] [3] [4] the ESBL producers among Gram-negative bacteria have been considered a major global public health threat. 5, 6 ESBLproducing Enterobacteriaceae are common in healthcare settings and they have also emerged in community settings. 7, 8 Although carbapenems have been considered a core treatment option for ESBL-related infections, the increased use of these antibiotics has created a new challenge, namely the emergence of carbapenemresistant bacteria. Since carbapenems are considered drugs of last resort for the treatment of ESBL-related infections, searching for alternative therapies among the existing drugs to reduce carbapenem use is indispensable. 9 Vardakas et al. 10 published a systematic review that compared the clinical effectiveness of carbapenems with that of alternative antibiotics in the treatment of patients with ESBL-positive V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. bacteraemia in 2012, but no updated systematic reviews have been published that embrace the latest evidence. One systematic review that was published in 2014 investigated the comparative mortality for carbapenems and b-lactam/b-lactamase inhibitor combinations (BL/BLIs), but the study focused on the treatment of sepsis. 11 This study aimed to systematically review recently published data to compare the clinical effectiveness of carbapenems with other antibiotics in the treatment of bacteraemia caused by ESBL-producing Enterobacteriaceae.
Methods

Literature search and study selection
A comprehensive search of the Ovid-Medline, Ovid-Embase, Cochrane Library and five Korean local databases (KoreaMed, KMBASE, RISS, KISS, NDSL) was performed until January 2016. We used the following key terms and their combinations without date or language restrictions: ('sepsis', 'bacteraemia', 'blood stream infection', 'systemic inflammatory response syndrome', 'multiple-organ dysfunction syndrome') and ('carbapenem', 'meropenem', 'ertapenem', 'doripenem', 'biapenem', imipenem', 'panipenem'). The references in the relevant articles were also searched manually to find additional eligible articles. The study's inclusion criteria were: (i) studies that included patients with ESBL-producing Enterobacteriaceae bacteraemia (ESBL-B); (ii) studies that reported the treatment outcomes of patients who had received carbapenems and alternative antibiotics; and (iii) articles published in English or Korean. Studies were excluded if they targeted children, did not have original data or were preclinical studies.
Quality assessment and data extraction
The Risk of Bias Assessment tool for Non-randomized Studies (RoBANS), version 2 was used to assess the methodological quality of the included studies. 12 The assessments were independently performed by two reviewers (S. K. S. and N. R. L.) and all of the discrepancies were resolved through discussion with a third reviewer (D. A. P.). The reviewers extracted the variables using a pre-designed data extraction form and they doublechecked them to avoid errors. When a full-text article was reported to contain insufficient data, the article's corresponding author was contacted to request additional data. If the relevant data being reported were from the systematic review previously published in 2012, 10 and there was no response from the corresponding author, the review's data were used for the current review.
Basic information about each study was collected, including its design, the country of origin, the number of organizations that participated, the patient enrolment period and the inclusion criteria. Information about the baseline demographic characteristics of study participants was collected, including their age and sex, and clinical information about the bacteraemia severity, comorbidities and bacterial source was recorded. The definition of the bacterial source was based on the definition provided in the publication.
The information collected about the treatment regimens included the drugs' names and therapeutic categories and their dosages and administration. BL/BLIs, cephalosporins, quinolones, aminoglycosides and others were included as alternatives to carbapenems. Non-carbapenems included all of the alternative antibiotics; non-BL/BLIs included all of them except for BL/BLIs.
Information about the overall mortality of the patients who received carbapenems or alternative antibiotics as empirical or definitive therapy to cure ESBL-B was extracted as the primary outcome. Sepsis-related mortality, adverse events and the patients' clinical or microbiological relapses were recorded as secondary outcomes. The preferred timepoint for these outcomes was 30 days, but if this information was unavailable, the end of treatment data or the end of the follow-up period data were extracted instead. The definitions of empirical therapy, definitive therapy, clinical relapse and microbiological relapse were the same as the definitions described in each publication.
Statistical analysis
For the dichotomous variables, the risk ratios (RRs) were calculated and reported with the 95% CIs. The v 2 test with a significance level set at P , 0.10 was used to assess the statistical heterogeneity among the studies, including the meta-analyses, and I 2 statistics were used to quantify the heterogeneity. Given the variability of the patient characteristics within the studies, the random-effects model was always applied as a conservative approach to all of the variables, regardless of the I 2 statistical data. Sensitivity and subgroup analyses and meta-regression models were used to investigate the sources of the heterogeneity and the factors that affect the magnitudes of effect. The sensitivity analyses were conducted to verify the hypothesis that using appropriate antibiotics might affect the mortality rate. The subgroup analyses were performed based on each study's purpose; that is, whether the studies were designed to compare the treatment effectiveness of the carbapenems with that of the other antibiotics. The meta-regression analysis explored the hypothesis that the bacterial source might affect the mortality rate, especially with respect to urinary infections. Egger's test and a funnel plot were used to detect publication biases associated with the variables used in 10 studies. 13, 14 All of the statistical analyses were conducted using Review Manager software, version 5.3 and Stata software, version 11.0. We used two-tailed tests of significance and P , 0.05 was considered statistically significant.
Results
After full-text reviews, 39 articles, including six studies that had insufficient data, were identified as being potentially relevant for this study. The corresponding authors of the six studies with insufficient data were contacted, [15] [16] [17] [18] [19] [20] and only one study's author provided additional data; 16 hence, the other studies were excluded. One additional publication was found during the hand search and 35 publications were finally selected for the meta-analysis ( Figure S1 , available as Supplementary data at JAC Online). 16, 38, 43 and one study was conducted in Singapore, 25 Japan, 22 France, 28 Canada 45 and Thailand. 46 Most of the studies were conducted in Asia (n " 19, 54%) and Europe (n " 9, 26%). None of the studies was a randomized controlled trial and 23 of the 35 studies (66%) were single-centre studies that collected the data retrospectively. 16, 21, [23] [24] [25] [26] 28, 30, 35, 36, 38, [40] [41] [42] [43] [44] [46] [47] [48] [49] 51, 53, 54 Nine were multicentre studies, 22, 31, 32, 34, 37, 39, 45, 52 and one of these prospectively collected the data from seven countries, namely South Africa, Taiwan, Australia, Argentina, USA, Belgium and Turkey. 52 Regarding the study participants, 11 studies investigated patients with bacteraemia caused by ESBL-producing or non-ESBL-producing Enterobacteriaceae 16, 22, 23, 38, 39, 41, 43, 44, 46, 51, 54 and 23 studies focused on patients with bacteraemia caused by ESBL-producing Enterobacteriaceae. 21, 24, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] 40, 42, 45, [47] [48] [49] [50] 52, 53 One study targeted patients with bacteraemia due to cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.
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The most frequently reported pathogens were E. coli (n " 23) 33, 44 four studies reported sepsis-related mortality. 24, 27, 31, 44 Clinical and microbiological relapses at 30 days and adverse events were reported in three and one studies, respectively. 22, 25, 28 The quality assessment using RoBANS, version 2.0, determined that the comparability of the participants had a low risk of bias in 7 studies (20.0%) 21, 24, 28, 31, 49, 50, 52 and that the confounding variables had a low risk of bias in 12 studies (34.3%) ( Figure S2 ). Table 2 summarizes the results from this meta-analysis with respect to the mortality outcomes. Of the 35 studies, 19 studies involving the empirical treatment of 2206 patients and 25 studies involving the definitive treatment of 1927 patients were included in the meta-analysis. Regarding overall mortality in all comparisons, the studies designed to compare treatment effectiveness between carbapenems and alternatives, and the others, were pooled separately as a subgroup analysis (Tables S2 and S3) .
Regarding empirical therapy, the groups that received carbapenems did not show statistically significant differences in relation to overall mortality compared with those that received non-carbapenems (RR 0.92, 95% CI 0.67-1.27, I
2 " 60%; Table 2 , Figure 1a ). Also there were no significant differences in overall mortality in subgroup analyses of carbapenems versus BL/BLIs (RR 1.01, 95% CI 0.74-1.38, I
2 " 16%; Table 2 , Figure 2a ), non-BL/BLIs (RR 0.85, 95% CI 0.56-1.29, I
2 " 59%; Table 2 , Figure S3 ), cephalosporins (RR 0.72, 95% CI 0.44-1.17, I
2 " 65%; Table 2 , Figure S4 ), quinolones (RR 0.64, 95% CI 0.34-1.21, I 2 " 47%; Table 2, Figure S5 ) and aminoglycosides (RR 0.81, 95% CI 0.29-2.30, I
2 " 27%; Table 2 , Figure S6 ). Of the 19 studies that were pooled and compared carbapenems with noncarbapenems, 10 studies, in which the study participants could be separated according to the appropriateness of the antibiotics used, were included in the sensitivity analysis. The pooled data from the 10 studies did not show a significant difference between carbapenem and non-carbapenem treatment (RR 0.78, 95% CI 0.38-1.62, I
2 " 72%; Table 2 , Figure S7 ). Thirteen studies that defined the patients' bacterial sources were included in the meta-regression analysis 21, 22, [29] [30] [31] [32] [33] [34] 42, 44, 46, 47, 50 and the associations between the mortality rates and the types of antibiotics used were not substantially altered by the presence of urinary tract infections or urosepsis (data not shown) (P" 0.325).
In relation to definitive therapy, the overall mortality was lower with carbapenem therapy than with non-carbapenem (RR 0.78, 95% CI 0.61-0.98, I
2 " 29%; Table 2 , Figure 1b ) or non-BL/BLI (RR 0.71, 95% CI 0.56-0.90, I
2 " 22%; Table 2 , Figure S8 ) therapy. In contrast, there were no significant differences with respect to the overall mortality rates between the carbapenem groups and the BL/BLI (RR 0.67, 95% CI 0.37-1.20, I
2 " 61%; Table 2 , Figure 2b ), quinolone (RR 0.77, 95% CI 0.45-1.30, I
2 " 0%; Table 2 , Figure S9 ) and aminoglycoside (RR 0.56, 95% CI 0.27-1.16, I
2 " 0%; Table 2 , Figure S10 ) groups. In the sensitivity analysis that excluded patients administered cephalosporins in the non-carbapenem or non-BL/BLI group, the carbapenems showed an equivalent overall mortality rate compared with the non-carbapenems (RR 0.95, Kang et Systematic review 95% CI 0.65-1.39, I 2 " 28%; Table 2 , Figure S11 ) and the non-BL/BLIs (RR 0.85, 95% CI 0.58-1.25, I
2 " 15%; Table 2 , Figure S12 ). The pooled data from 13 studies showed that compared with the cephalosporins, the carbapenems had a lower overall mortality rate (RR 0.56, 95% CI 0.42-0.74, I
2 " 26%; Table 2 , Figure S13 ). Fourteen studies that defined the patients' bacterial sources were included in the meta-regression analysis that showed that the association between the mortality rate and the antibiotic type was substantially altered by the presence of a urinary tract infection or urosepsis (data not shown) (P " 0.019). 22, 24, 25, 27, [30] [31] [32] [33] 36, 44, 49, 50, 52, 54 We performed additional subgroup analyses according to geographical location for two comparison arms: carbapenems versus non-carbapenems and carbapenems versus BL/BLIs, but found no clear or consistent pattern of difference ( Figures S14-S17) .
Three studies reported microbiological relapses within 30 days in patients treated with carbapenems, BL/BLIs, cephalosporins and non-carbapenems. There was no significant difference between the carbapenems and the non-carbapenems with respect to the relapse rates within 30 days (RR 2.27, 95% CI 0.54-9.54, I 2 " 0%; Figure S18 ).
Discussion
We conducted a systematic review and meta-analysis that compared the treatment effectiveness of carbapenems and alternative antibiotics in patients with ESBL-B. Although a meta-analysis was published in 2012, 10 our study included the most recent publications and it reflects the latest data on the relative effectiveness of the antibiotics. Unlike the previous study, 10 the findings from this meta-analysis showed that overall mortality did not differ when carbapenems were compared with non-BL/BLIs, with cephalosporins or with BL/BLIs in empirical therapy, or when carbapenems were compared with quinolones in definitive therapy. The current meta-analysis supports the findings from the previous meta-analysis that showed that carbapenems were associated with lower overall mortality rates compared with non-BL/BLIs or cephalosporins administered alone in definitive therapy. Additionally, the sensitivity analysis that excluded patients administered cephalosporins in the non-BL/BLI group did not demonstrate a difference between carbapenems and non-BL/BLIs with respect to mortality. Finally, there were no differences between carbapenems and alternative antibiotics in relation to sepsisrelated mortality or microbiological relapses.
The previous systematic review reported that patients who received carbapenems as empirical therapy had lower mortality rates compared with those administered non-BL/BLIs, cephalosporins or quinolones 10 but the current analysis did not support the favourable findings relating to the carbapenem group. The current study included a greater number of relevant studies; hence, this study's pooled data were derived from larger sample sizes compared with those used in the previous study; 1299 versus 503 patients, respectively, for non-BL/BLIs; 890 versus 270 patients, respectively, for cephalosporins; and 457 versus 229 patients, respectively, for quinolones. The larger and somewhat more heterogeneous data are the basis for the greater heterogeneity within our findings compared with the previous study's findings.
Regarding definitive therapy, our meta-analysis showed that compared with non-carbapenems, carbapenems were associated with lower mortality rates and that the heterogeneity among the included studies was not significant. Considering the presence of potential heterogeneity, we performed two additional analyses: a sensitivity analysis in which we excluded the data from patients administered cephalosporins and a meta-regression analysis that accounted for the proportion of urinary tract infections as bacterial sources. In the sensitivity analysis that included patients who received non-carbapenems but excluded those administered cephalosporins, the difference between the two groups regarding the mortality rate disappeared, which supports a previous finding that indicated that cephalosporins were inferior at treating severe infections caused by ESBL-producing Enterobacteriaceae. 55 When choosing an empirical treatment regimen, the bacteraemia severity, the bacterial source and the patient's disease history should be comprehensively reviewed. In our analysis, the publications from two studies that compared the effectiveness of carbapenems and BL/BLIs 21, 35 showed discrepancies in their conclusions about which drug should be used in empirical therapy. In relation to choosing a definitive treatment regimen, our data from the subgroup analysis, including two studies aiming to compare the mortality of carbapenems and BL/BLIs, suggested that administering BL/BLIs might be reasonable when the bacteria are susceptible to BL/BLIs and this might support efforts to reduce the overuse of carbapenems in clinical scenarios. 25, 33 Amongst the included studies, 11 reported the susceptibility rate of ESBL-producing Enterobacteriaceae to carbapenems or BL/BLIs. 16, 25, 27, 29, 30, 32, 42, 47, [49] [50] [51] The susceptibility of ESBLproducing Enterobacteriaceae to carbapenems ranged from 95% to 100%, and susceptibility to amoxicillin/clavulanate and piperacillin/tazobactam varied from 40% to 100% and from 54% to 100%, respectively. One study reported that the susceptibilities of K. pneumoniae and P. mirabilis to imipenem were 95% and all others were susceptible to carbapenems. 42, 25, 27, 30, 47, [49] [50] [51] For amoxicillin/clavulanate, the susceptibility of E. coli ranged from 40% to 46%, and that of K. pneumoniae was 55%; the reported susceptibility of P. mirabilis was between 52% and 100%. 25, 27, 30, 47, 55 For piperacillin/tazobactam, the susceptibility of E. coli and K. pneumoniae varied between 59% and 100% and between 54% and 100%, respectively. 16, 25, 30, 42, 47 The susceptibility of P. mirabilis to piperacillin/tazobactam ranged from 90% to 100%. 27, 42, 47, 55 These results support the suggestion from the previous meta-analysis that a carbapenem would be a favourable treatment option in empirical therapy. 10 However, it still needs further investigation regarding the finding because of geographical limitation of the included studies, which were performed in Asia and southern Europe only (Table S1) .
These results must be interpreted with caution in the context of the study's limitations. First, most of the studies included were not designed to compare the clinical outcomes of carbapenems and alternative antibiotics for treating patients with ESBL-B. Compared with the previous systematic review, we included publications that described studies designed to compare the clinical effectiveness of carbapenems and alternative antibiotics, but the number of available studies was too small to enable clear conclusions to be drawn. Consequently, our data could not control for potential biases. In this study, the result based on more than five studies designed to compare the clinical effectiveness of carbapenems and specific alternative options was only for the comparison between carbapenems and cephalosporins in definitive therapy.
Systematic review JAC Second, the cohorts that were pooled for the meta-analysis were heterogeneous with respect to the participants' characteristics in the carbapenem and the alternative antibiotic groups, which likely reduced the comparability of the data. In this study, the publication dates of the reports spanned from 2002 to 2015. Twentyone studies focused on bacteraemia caused by E. coli or K. pneumoniae, whereas the others included bacteraemia caused by E. cloacae, P. mirabilis and other bacterial species. The bacterial sources and the acquisition routes were also mixed. Additional analyses of these factors might provide relevant information to guide the selection of treatment regimens, but this could not be conducted in this study because the necessary information was not available for meta-analysis.
Third, the included studies did not have homogeneous intervention characteristics. Several studies did not discriminate between patients administered a single antibiotic and those administered combination therapy. Furthermore, most of the publications did not describe the antibiotic treatment regimens. Thus, the heterogeneity of the patients' and the interventions' characteristics could act as confounding factors that affect the mortality rates.
Fourth, the results from the subgroup analyses in this study should be interpreted very carefully. In this study we performed multiple subgroup analyses according to study design, study location and generation of antibiotics and the results from these provided informative findings. As multiple subgroup analyses increase the risk of false-positive findings, the results of the subgroup analysis here should be considered preliminary.
Fifth, publication bias was tested using a funnel plot and the plot asymmetry was confirmed by Egger's test (Table 2, Figure S19 ). However, for dichotomous outcomes with intervention effects estimated as RRs, 'firm guidance is not yet available as to the model that can be used to explore further a possible asymmetry'; therefore, appropriate interpretation of the test's results requires caution. 10, 56 In conclusion, our data showed that BL/BLIs are not inferior to carbapenems for the definitive therapy of ESBL-B if the bacteria are susceptible to them. However, cephalosporins seemed to be associated with higher mortality rates compared with carbapenems. Although the use of BL/BLIs, quinolones and aminoglycosides in empirical therapy and the use of quinolones and aminoglycosides in definitive therapy showed equivalent mortality rates compared with carbapenems, the pooled data were insufficient to enable clear conclusions to be drawn, because few of the available studies addressed this specific question. To investigate the clinical effectiveness of carbapenems and alternative antibiotics in the treatment of bacteraemia caused by ESBL-producing Enterobacteriaceae, randomized controlled trials with large sample sizes are needed.
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